ライフサイエンスコーパス: echocardiogram

1 n evidence-based medical therapies (baseline echocardiogram).

2 monary artery systolic pressure >40 mm Hg on echocardiogram).

3 n relation to changes in LVEF on a follow-up echocardiogram.

4 002 and 2014, including 95 with an available echocardiogram.

5 citation myocardial function was measured by echocardiogram.

6 rdiogram 30 days to 2 years from the initial echocardiogram.

7 e incremental prognostic value of a complete echocardiogram.

8 subjects would test positive and require an echocardiogram.

9 and 1 had left ventricular noncompaction on echocardiogram.

10 , 2 24-h ABP recordings, and a 2-dimensional echocardiogram.

11 ll thickness and LVOTG were measured with an echocardiogram.

12 nd to develop a new tool for assessing PR by echocardiogram.

13 ortic valve regurgitation at the time of the echocardiogram.

14 uzumab and had a pre-treatment and follow-up echocardiogram.

15 opment of third-degree CHB detected by fetal echocardiogram.

16 ac vegetations identified by transesophageal echocardiogram.

17 evidence of stenosis or regurgitation on an echocardiogram.

18 Heart Association-recommended comprehensive echocardiogram.

19 did not receive contrast during their stress echocardiogram.

20 ed to become an integral part of the routine echocardiogram.

21 onal impairment could be detected in vivo by echocardiogram.

22 ociated with worsening diastolic function on echocardiogram.

23 ht ventricular size and function as shown by echocardiogram.

24 rison group) was assessed with transthoracic echocardiogram.

25 s and were screened for cardiac function via echocardiograms.

26 ncluded 97 829 patients with paired ECGs and echocardiograms.

27 ct annual health and safety reviews of these echocardiograms.

28 age, sex, initial LVEF, and interval between echocardiograms.

29 gs who were heterozygous carriers had normal echocardiograms.

30 DMT alone; 599 had core laboratory evaluable echocardiograms.

31 amyloid extent than in subjects with typical echocardiograms.

32 d LVEF was measured from baseline and 5-year echocardiograms.

33 cardiovascular biomarkers, and transthoracic echocardiograms.

34 t the inclusion criteria, 741 (85%) had both echocardiograms.

35 2 months), and 27% had persistently abnormal echocardiograms.

36 This analysis includes 2037 echocardiograms.

37 cal history, physical examination, ECGs, and echocardiograms.

38 , 130 children (2.7%) had abnormal screening echocardiograms.

39 R was higher (P=0.01) compared with pre-BAVP echocardiograms.

40 on of sinus rhythm was assessed by follow-up echocardiograms.

41 ac amyloidosis who underwent transesophageal echocardiograms.

42 ocardiographic core laboratory evaluated all echocardiograms.

43 Medicine Fellows performed 154 goal-directed echocardiograms, 110 with complete cardiology-reviewed t

44 rdiac thrombus identified on transesophageal echocardiogram (13 of 16 [81%] vs. 2 of 8 [25%]; p = 0.0

45 -enhanced cardiovascular magnetic resonance, echocardiograms, 24-hour blood pressure monitoring, and

46 t diagnosis and who had at least 1 follow-up echocardiogram 30 days to 2 years from the initial echoc

47 At the time of the initial echocardiogram, 323 patients (38%) were taking bisphosph

48 %-53.6%), bone density studies (6.3%-20.0%), echocardiograms (5.0%-7.8%), magnetic resonance imaging

49 vere left ventricular dysfunction on initial echocardiogram (80%) and/or the need for intravenous ino

50 Among 971 patients with evaluable echocardiograms (92%), LF (stroke volume index </=35 mL/

51 Repeat echocardiogram after recovery from the sepsis episode de

52 fusing capacity, and pericardial effusion on echocardiogram all predicted mortality.

53 ass index and coronary artery calcification; echocardiograms also were obtained in 58 subjects withou

54 nts assessed for transplantation, 739 had an echocardiogram and 217 of 739 (29%) died during a mean f

55 Each patient underwent a comprehensive echocardiogram and a myocardial perfusion scintigraphy (

56 All subjects had an echocardiogram and an exercise ECG performed, followed b

57 tudy and underwent a standardized functional echocardiogram and biomarker collection.

58 A total of 277 preterm infants completed echocardiogram and BPD assessments at 36 weeks PMA.

59 y of Fallot (n=143; 12.5+/-3.2 years) had an echocardiogram and CMR within 3 months of each other.

60 Preprocedure transesophageal echocardiogram and computed tomography/magnetic resonanc

61 Central laboratories analyzed echocardiogram and CT images.

62 ately after a standardized dobutamine stress echocardiogram and decreased after 1 hour.

63 , and a cardiology evaluation which included echocardiogram and electrocardiogram.

64 nd cardiac function was evaluated in vivo by echocardiogram and in vitro by isolated papillary muscle

65 ng recipients had normal cardiac function on echocardiogram and no evidence of acute rejection on dis

66 zed with HFpEF between 2005 and 2016 in whom echocardiogram and NT-proBNP were both available at the

67 ction, in addition to simple two-dimensional echocardiogram and radionucleotide angiography, has also

68 n at a referral PH clinic with transthoracic echocardiogram and right heart catheterization within 1

69 Median time difference between goal-directed echocardiogram and transthoracic echocardiography was 21

70 Echocardiograms and 2-dimensional strain analysis were o

71 A total of 984 participants with evaluable echocardiograms and baseline LF AS (LVSVI </=35 mL/m2) w

72 ir cancer therapy (total of 15 months) using echocardiograms and blood samples.

73 fires were prospectively enrolled and serial echocardiograms and cardiac troponin I evaluations were

74 this study, 162 subjects with CKD underwent echocardiograms and computed tomography scans to assess

75 Echocardiograms and computed tomography scans were revie

76 Two hundred twenty-five echocardiograms and concomitant high-sensitivity troponi

77 dicine Fellow's performance of goal-directed echocardiograms and intensivists' interpretations for ev

78 Patients had echocardiograms and measures of B-type natriuretic pepti

79 VAD were prospectively evaluated with serial echocardiograms and right heart catheterizations.

80 Echocardiograms and serial serum measurements of cardiac

81 red in two established technologies: resting echocardiograms and stress tests with nuclear imaging.

82 ients undergoing CRT with available baseline echocardiograms and subsequent clinical and echocardiogr

83 ts who underwent CRT with available baseline echocardiograms and subsequent clinical and echocardiogr

84 tum, 56% of women with CHD had comprehensive echocardiograms and, during pregnancy, 4% filled potenti

85 ac vegetations identified by transesophageal echocardiogram, and all underwent percutaneous lead extr

86 cardiac stress positron emission tomography, echocardiogram, and renal function ascertainment at Brig

87 tolic function was assessed by transthoracic echocardiogram, and systolic dysfunction was defined as

88 vation duration (TAD), and RV enlargement by echocardiogram, and together with JUP mutation met defin

89 Clinical data, transthoracic echocardiograms, and brain imaging of 53 consecutive pat

90 Plasma, echocardiograms, and clinical outcomes were collected at

91 Clinical assessment (including vital signs, echocardiograms, and electrocardiographs) and testing of

92 We analysed all CT scans, echocardiograms, and neurological events in a masked fas

93 The components of a fetal echocardiogram are described in detail, including descri

94 performed and documented their goal-directed echocardiogram as normal or abnormal for right ventricul

95 Thirty-two patients (32%) had a normal echocardiogram at baseline.

96 diography before CRT and underwent follow-up echocardiograms at 1 year.

97 Post-procedural echocardiograms at 48 h, 1 month, and 2 months demonstra

98 Echocardiograms at 7 days of age may be a useful tool to

99 CD rate in 139 participants with quantitated echocardiograms at all time points.

100 Patients were assigned to CRT-D with paired echocardiograms at baseline and at 12 months (n = 752).

101 MADIT-CRT) trial who survived and had paired echocardiograms at enrollment and at 12 months (n=752) w

102 Only those who had follow-up echocardiograms at least a year apart were included.

103 Included patients had echocardiograms at the time of ablation and at 1-year cl

104 Serial echocardiograms (at 1, 2, 3, 4, 6, 9, and 12 months) and

105 Of the 24 patients who had echocardiograms available for reread, there was a respon

106 easible for 90 of the 96 patients (94%) with echocardiograms available.

107 Time from presentation to the echocardiogram before left ventricular fractional shorte

108 ontinue to routinely perform transesophageal echocardiograms before atrial fibrillation (AF) ablation

109 ams of consecutive patients who had baseline echocardiograms between January 1, 2005, and December 31

110 t baseline cardiopulmonary exercise testing, echocardiogram, biomarker assessment, and rhythm status

111 Results of audiology testing, echocardiogram, brain magnetic resonance imaging, renal

112 esented to our institution with a diagnostic echocardiogram but a normal ECG.

113 edures could be done without transesophageal echocardiogram but used intracardiac echocardiography im

114 Group (IGHG) recommends risk-based screening echocardiograms, but evidence supporting its frequency a

115 ac vegetations identified on transesophageal echocardiogram can safely undergo complete device extrac

116 Trends regarding use of echocardiograms, changing drug therapy for Marfan syndro

117 f the findings of right heart dysfunction on echocardiograms, computed tomography angiography, or car

118 A comprehensive echocardiogram consisting of 2-dimensional (2D) and 3-di

119 f 45), or mild POPH (n = 11 of 18) or normal echocardiograms (controls, n = 86 of 122) (P = .77).

120 in 71 (86%) of 83 patients who had available echocardiogram data and imaging.

121 randomized subjects, 624 had paired Doppler echocardiogram data for >/=1 analyses at 6, 12, 18, or 2

122 Five-year echocardiogram data were available for 424 patients afte

123 Using paired 12-lead ECG and echocardiogram data, including the left ventricular ejec

124 On the basis of echocardiogram data, pHTN was defined as right ventricul

125 Ventricular function on early echocardiograms, defined as obtained within the first 48

126 e albumin/creatinine >30 mg/g) and available echocardiogram-derived pulmonary artery systolic pressur

127 ture and measurement of heart function using echocardiogram/Doppler parameters.

128 lide (RN) stress test or a dobutamine stress echocardiogram (DSE).

129 Noninvasive assessment relies on echocardiograms (echos), which are technically challengi

130 Serial evaluations included echocardiogram, electrocardiogram, and blood collection

131 ants with birthweights 500-1,250 g underwent echocardiogram evaluations at 7 days of age (early) and

132 coronary artery disease risk scores with an echocardiogram, exercise stress test, computerized tomog

133 onist clenbuterol and were regularly tested (echocardiograms, exercise tests, catheterizations) with

134 nor significant differences in prior ECG or echocardiogram findings compared with matched controls w

135 Patients underwent a 3-dimensional echocardiogram focused on the tricuspid apparatus.

136 ram changes and wall motion abnormalities on echocardiogram following neurologic injury.

137 Despite standard guidelines that recommend echocardiogram for screening before transplantation, fou

138 of the NBA mandates annual preseason stress echocardiograms for each player.

139 Echocardiograms from 120 adolescents investigated for AR

140 ograms from 74 HAART-exposed children to 860 echocardiograms from 140 HAART-unexposed but HIV-infecte

141 d Children) study prospectively compared 148 echocardiograms from 74 HAART-exposed children to 860 ec

142 ars with cardiovascular risk factor data and echocardiograms from CARDIA year 5 and 25 examinations.

143 We performed speckle-tracking analysis of echocardiograms from participants in the Hypertension Ge

144 index) and 60 randomly selected preoperative echocardiograms from patients with presumed balanced AVS

145 We studied serial echocardiograms from presentation until the last follow-

146 (A Longitudinal Cohort Study of Echocardiograms From Public and Private Echocardiography

147 ine, 30-day, and 1- and 2-year transthoracic echocardiograms from the PARTNER (Placement of Aortic Tr

148 tertile of rarely appropriate transthoracic echocardiograms had significantly lower odds of receivin

149 ants were divided into 3 categories based on echocardiograms: HF-REF if EF was <50%, HF-PEF if EF was

150 We examined absolute GLS on the baseline echocardiogram in relation to changes in LVEF on a follo

151 n the cohort was restricted to those with an echocardiogram in the prior 30 days and no intervening e

152 We performed echocardiograms in 43 patients who met the following inc

153 d functional measures on clinically acquired echocardiograms in children with CKD.

154 We used serial routine echocardiograms in participants of the Framingham Heart

155 a high frequency of low-value transthoracic echocardiograms in patients with CAD and whether practic

156 re evaluated longitudinally with a series of echocardiograms in the first trimester, in the third tri

157 We included 761 subjects (3134 echocardiograms) in final analyses.

158 =18 years of age at 19 centers with a normal echocardiogram included age, sex, race, ethnicity, heigh

159 Echocardiogram, invasive hemodynamic pressure-volume ana

160 Transesophageal echocardiogram is a readily available diagnostic tool th

161 An echocardiogram is indicated in the presence of symptoms

162 enario for which the indication for a stress echocardiogram is uncertain.

163 aluated measures from prior clinical ECG and echocardiograms, manually over-read to evaluate ARVC dia

164 evated pulmonary artery systolic pressure on echocardiogram, may identify an at-risk population that

165 se, and had acceptable quality 3-dimensional echocardiograms (mean age, 76+/-5 years; 59% women).

166 of cardiac or pulmonary compression on CT or echocardiogram, mitral valve prolapse, arrhythmia, or re

167 elin-1 levels and tricuspid regurgitation on echocardiogram (n = 3223) at the time of first examinati

168 oup with pretransplant electrocardiogram and echocardiogram (n=166 and n=112, HR 4.75, 95% CI 2.07-10

169 Fetal echocardiograms, neonatal ECG, and genetic testing were

170 jority were symptomatic at the time of index echocardiogram (New York Heart Association [NYHA] functi

171 who had systolic blood pressure (SBP) and an echocardiogram obtained 30 days after TAVR.

172 Transthoracic echocardiograms obtained at baseline and at 30 days and

173 Transthoracic echocardiograms obtained during evaluation for transplan

174 ea (EDA) was calculated from transesophageal echocardiograms obtained during initiation and weaning o

175 Multiple echocardiograms obtained since birth, cardiac MR images

176 F improvement included presence of AF during echocardiogram (odds ratio, 4.22 [95% CI, 1.71-10.4], P=

177 reviewed the intraoperative transesophageal echocardiograms of 13,092 patients without prior diagnos

178 We reviewed the clinical records and echocardiograms of 20 affected patients encountered in o

179 We studied 200 serial echocardiograms of 48 children with DCM (7.0+/-6.0 years

180 this cohort study, first- and last-available echocardiograms of 85 patients with ARVD/C fulfilling 20

181 Echocardiograms of affected cats revealed a high prevale

182 We reviewed echocardiograms of all cardiac donors in the United Netw

183 analyzed core laboratory-generated data from echocardiograms of all patients enrolled in the Placemen

184 tudied all transthoracic and transesophageal echocardiograms of cardiac amyloid patients at the Mayo

185 We reviewed clinical records and echocardiograms of consecutive patients who had baseline

186 nal cohort of complete AVSD, 52 preoperative echocardiograms of patients with presumed right dominant

187 requency of rarely appropriate transthoracic echocardiograms on healthcare utilization and patient ou

188 ulum followed by performing 20 transthoracic echocardiograms on patients receiving invasive mechanica

189 ection fraction (EF) </=45% as determined by echocardiogram or left ventriculogram within 12 hours of

190 iduals for 9 cardiac phenotypes (assessed by echocardiogram or magnetic resonance imaging) to 2.5 mil

191 icular ejection fraction of at least 55% (by echocardiogram or multiple-gated acquisition scan).

192 nce of PPM was identified from postoperative echocardiograms or preoperative manufacturer-provided ch

193 In a series of 10 638 echocardiograms, our view selection model identified 645

194 (Tras), or both (Dox+Tras), we obtained 1249 echocardiograms over a median follow-up of 2.0 (interqua

195 ly improved in patients with normal baseline echocardiograms (p=0.005) or electrocardiographs (p=0.05

196 On follow-up echocardiogram, patients in continuous sinus rhythm had

197 013 and who had baseline and post-transplant echocardiograms; patients with simultaneous heart transp

198 acquired on the date of the ED visit and an echocardiogram performed within 30 days of presentation.

199 aminations, and 19th and 20th examinations), echocardiograms performed by trainees were compared with

200 coronary artery bypass grafting underwent an echocardiogram, plasma biomarker determination, and intr

201 All patients (100%) had a transesophageal echocardiogram prior to DCCV.

202 strategies, intra-operative transesophageal echocardiogram, pulmonary artery catheterization, cardio

203 ons, brain magnetic resonance imaging (MRI), echocardiograms, pulmonary function tests, and physical

204 At baseline transthoracic echocardiogram, pure AR versus AR + OMR versus AR + FMR

205 ith intracardiac thrombus on transesophageal echocardiogram received adequate anticoagulation >=3 wee

206 Of this cohort, 22.3% had abnormal echocardiogram: reduced left ventricular ejection fracti

207 of 122 consecutive patients referred for an echocardiogram regardless of the admitting diagnosis.

208 -up, the maximum pulmonary valve gradient by echocardiogram remained significantly reduced relative t

209 Between January 2011 and January 2014, 2093 echocardiograms reported moderate or greater aortic sten

210 Clinical characteristics and echocardiogram reports were abstracted.

211 f LVT was conducted using 90,065 consecutive echocardiogram reports.

212 ECG and echocardiogram results were classified by blinded core l

213 Evaluation of the most recent outpatient echocardiogram revealed an average peak instantaneous gr

214 rfarin therapy if the 45-day Transesophageal echocardiogram revealed either minimal or no peri-device

215 A baseline echocardiogram revealed normal left ventricular (LV) sys

216 Transesophageal-echocardiogram revealed thrombus within the left atrium

217 On echocardiogram, RV function was assessed by (1) Doppler

218 iers without left ventricular hypertrophy on echocardiogram, SCD occurred, myocyte disarray was found

219 y of ablation for AF without transesophageal echocardiogram screening or intracardiac echocardiograph

220 s could be performed without transesophageal echocardiogram screening or intracardiac echocardiograph

221 The echocardiogram showed an abrupt increase in the severity

222 Repeat echocardiogram showed an enlarged LV with moderate to se

223 rformed on schedule unless the goal-directed echocardiogram showed critical findings.

224 olic and systolic time-velocity integrals on echocardiogram showed moderate correlation with RF on CM

225 At the time of referral, Doppler echocardiograms showed major mechanical dyssynchrony at

226 detected at a median of 6 months after prior echocardiograms showing mild or less gradients.

227 known LVEF <50%, patients undergoing only 1 echocardiogram study, and those with a diagnosis of dila

228 After a rapid bedside echocardiogram suggesting pulmonary embolus, thrombolyti

229 a prospective multisite cohort study design, echocardiograms taken between birth and 24 months were c

230 require a routine screening transesophageal echocardiogram (TEE) before pulmonary vein isolation (PV

231 Transesophageal echocardiogram (TEE) is considered the gold standard mod

232 Transesophageal echocardiogram (TEE) is generally recommended for all pa

233 elative contraindications to transesophageal echocardiogram (TEE), revealed in a hemophilic patient,

234 From the 14-month to pre-Fontan echocardiogram, the MBTS group had stable indexed RV vol

235 On the most recent echocardiogram, the median left ventricular end-diastoli

236 ntext of a patient's age and the rest of the echocardiogram to describe diastolic function and guide

237 to compare measures of PR and RV function on echocardiogram to those on cardiac magnetic resonance (C

238 iptional profiling, virology, histology, and echocardiograms to investigate the role of a high-fat di

239 y mitral regurgitation (MR) in transthoracic echocardiogram (TTE) due to relative contraindications t

240 se criteria (AUC) have defined transthoracic echocardiogram (TTE) indications for which there is a cl

241 or hearts with LVSD on initial transthoracic echocardiogram (TTE) that resolved during donor manageme

242 tolic pulmonary artery pressure >35 mm Hg on echocardiogram underwent a right heart catheterization.

243 Trained on echocardiogram videos, our model accurately segments the

244 vailable a large dataset of 10,030 annotated echocardiogram videos.

245 Median time from ECG to echocardiogram was 1 day (Q1: 1, Q3: 2).

246 Abnormal echocardiogram was independently associated with all cau

247 Of note, an echocardiogram was not repeated before the start of inte

248 ation functional class was reassessed and an echocardiogram was obtained and compared with pre-CRT.

249 Echocardiogram was positive by transesophageal route (TE

250 f 138 SSc patients with technically adequate echocardiograms was studied and compared with 40 age- an

251 l of 10 471 individual patient transthoracic echocardiograms, we identified moderate or severe PH in

252 our systemic markers (cardiac involvement by echocardiogram, weight loss > 10 pounds, orthostatic int

253 gnosis of HF before or within 30 days of the echocardiogram were excluded.

254 2013, and had a postoperative transthoracic echocardiogram were included.

255 Severely abnormal hemodynamics on echocardiograms were also infrequent and not associated

256 Echocardiograms were also obtained at years 8 to 9 in a

257 Echocardiograms were analyzed according to established g

258 ECGs and echocardiograms were analyzed independently, blinded to

259 Acceptable echocardiograms were available at both time points in 24

260 in Results: Cardiac function data from early echocardiograms were available for 1,173 (71%) cases and

261 Echocardiograms were collected using a common protocol,

262 Their baseline and 12-month echocardiograms were compared between the group with and

263 Most recent echocardiograms were evaluated for right ventricular out

264 igh rate of rarely appropriate transthoracic echocardiograms were less likely to receive potentially

265 Electrocardiograms (ECGs) and echocardiograms were normal in 16 and 17 patients, respe

266 Echocardiograms were obtained 1 year after study entry a

267 Standardized echocardiograms were obtained at baseline and during reg

268 Echocardiograms were obtained at baseline, discharge, 30

269 Echocardiograms were obtained at baseline, discharge, 30

270 Centrally interpreted echocardiograms were obtained at KD diagnosis and 1 and

271 Doppler echocardiograms were obtained at randomization (after 30

272 ood samples, electrocardiographs (ECGs), and echocardiograms were obtained before, during, and after

273 Echocardiograms were obtained from 935 patients with HFp

274 METHODS AND In 8 centers, echocardiograms were obtained on 169 patients prospectiv

275 Echocardiograms were obtained on 2383 participants (1993

276 Echocardiograms were performed at 30 days and 1 year pos

277 Echocardiograms were performed at 7 days and 36 weeks PM

278 Echocardiograms were performed at baseline, discharge, 3

279 Echocardiograms were performed at least every 3 weeks fr

280 ressive pharmacological regimen, and regular echocardiograms were performed at reduced LVAD speed (60

281 Diabetes Mellitus in Adolescents and Youth), echocardiograms were performed at study years 4 to 5 and

282 Echocardiograms were performed on 1,013 participants usi

283 Echocardiograms were performed to assess systolic and di

284 uring the study period, approximately 50,660 echocardiograms were performed.

285 All echocardiograms were re-reviewed by experts (2012 World

286 Doppler echocardiograms were recorded at baseline, before hospit

287 Echocardiograms were reported in a standardized, blinded

288 Comprehensive echocardiograms were reviewed in blinded fashion.

289 Echocardiograms were used to measure cardiac mechanics:

290 Twenty-three studies (1,638 echocardiograms) were included.

291 ed systolic function, as assessed on a study echocardiogram when the participants were 23 to 35 years

292 patients with a reduced LVEF <50% (screening echocardiogram), whose LVEF had increased by at least 10

293 ol) from 2004 to 2017 who had >=1 subsequent echocardiogram with quantitation were included.

294 sence of PFO was determined by transthoracic echocardiogram with second harmonic imaging and transcra

295 clinicians, including the integration of the echocardiogram with the history and physical examination

296 rtension Genetic Epidemiology Network) study echocardiograms with available urinary sodium data (N =

297 and 49 years of age, and 872 had a screening echocardiogram, with 573 (66%) measuring an EF >50%.

298 severe traumatic brain injury; transthoracic echocardiogram within 1 day after mild traumatic brain i

299 Transthoracic echocardiogram within 1 day and over the first week afte

300 >/=55% and who subsequently had a follow-up echocardiogram within 6 to 24 months.